VRDN

VRDN

Viridian Therapeutics Inc

Viridian Therapeutics develops and commercializes therapies for serious and rare diseases, focusing on IGF-1R treatments for thyroid eye disease and therapies for Graves' disease, utilizing monoclonal antibodies and engineered inhibitors for targeted outcomes.

โš•๏ธ Healthcare NASDAQ Listed 2014 $ USD
$1,000 invested 10 years ago โ†’$199today

Score Overview

1 Year
Score
Net Growth-12.95%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth0.39%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score1.9
Net Growth-387.29%
Net TrendNever
Net Income Consistencyโ€”
Rev Growth24x
Rev Trend40%
Revenue Consistencyโ€”
10 Years
Score
Net Growth-28x
Net Trend10%
Net Income Consistency
Rev Growth21x
Rev Trend50%
Revenue Consistency
All Time
Score
Net Growth-47x
Net Trend8%
Net Income Consistency
Rev Growth16x
Rev Trend50%
Revenue Consistency

See the full market ranking โ†’

Viridian Therapeutics Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 1M to $ 70M and net income went from -$ 110M to -$ 342M. Revenue increased in 2 of those 5 years; net income in 0.

Between 2015 and 2025, revenue grew from $ 2M to $ 70M and net income went from -$ 11M to -$ 342M. Revenue increased in 5 of those 10 years; net income in 1.

Viridian Therapeutics Inc currently holds a 5-year HDB Score of 1.9 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 22.88โ€”
1 Year2025-08-12
$ 17.9727.32%
5 Years2021-08-12
$ 11.8393.41%
10 Years2016-08-12
$ 114.75-80.06%
All Time2014-06-18
$ 2.05K-98.88%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 71M-$ 386M$ 981M
2025$ 70M-$ 342M$ 874M
2024$ 302K-$ 269M$ 717M
2023$ 314K-$ 237M$ 477M
2022$ 1M-$ 129M$ 424M
2021$ 2M-$ 79M$ 196M
2020$ 1M-$ 110M$ 127M
2019$ 4M-$ 41M$ 26M
2018$ 8M-$ 32M$ 62M
2017$ 4M-$ 26M$ 47M
2016$ 3M-$ 12M$ 3M
2015$ 2M-$ 11M$ 10M
IPO2014$ 4M-$ 7M$ 5M

Explore beyond VRDN

You're looking at Viridian Therapeutics Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies